8 research outputs found
WHO-ISG collaboration on assistive technologies for healthy ageing-in-place:A round table discussion
Assistive Technology (AT) is used at various points in the lifespan by those coping with either short-term or long-term impairments, which can involve living with chronic conditions and/or comorbidities. In the case of older adults, AT can support or compensate for the functional or cognitive declines that they are likely to face in later life. AT can be integrated as part of smart homes (see Figure 1 from van Dijken et al, 2006); and should be safe to use, effective, easy to access, affordable, and not seen as stigmatising. In addition, AT should support older adults to have a meaningful life while building self-esteem, and autonomy and promoting social participation and community engagement. For this roundtable discussion, we present and discuss a WHO-ISG collaborative project focused on Assistive Technology for Healthy Ageing. For this project, we consider applications and use AT not only from a medical standpoint but also situated within a social perspective in the context of Gerontechnology. Results and propositions according to the WHO-UNICEF global report on assistive technology were applied as a starting point for this project (WHO, 2022), prioritising the potential benefits to individuals, their communities, and society and with a focus on identifying potential barriers that may occur and how to mitigate them
Caracterização morfológica e imuno-histoquímica de lesões em casos de aborto bovino bacteriano e viral no sul de Minas Gerais
MEJORAMIENTO DEL RENDIMIENTO Y CALIDAD DE FRUTO Y PSEUDOFRUTO DE MARAÑON CON UN CICLO DE FERTILIZACIÓN ORGÁNICA
Seroprevalence of rubella in urban and rural populations, Guaratinguetá
OBJETIVO: Determinar a prevalência de anticorpos para a rubéola na população de 15 a 39 anos no município de Guaratinguetá, São Paulo, SP. MÉTODOS: Neste estudo, 996 amostras foram colhidas após consentimento informado e esclarecido entre homens e mulheres na faixa etária de 15 a 39 anos. Os anticorpos da classe IgG foram detectados por ELISA usando kit comercial Rubenostika IgGII (Organon Teknika AS, Holland). As faixas etárias foram estratificadas em três categorias: 15-19 anos; 20-29 anos e 30-39 anos. As análises estatísticas foram realizadas pelo software MINITAB versão 14.0 (Minitab Inc, EUA). RESULTADOS: A proporção de soros reagentes para anticorpos da classe IgG nas faixas etárias estudadas foram: 92,7% positivos de 15-19 anos; 82,4% de 20 a 29 anos e 90,7% de 30-39 anos com diferença significativa na proporção de soropositivos pela faixa etária ( p < 0,001 ). A variação de intensidade da resposta anticórpica foi calculada e os resultados mostram que há diferença significativa (p = 0,002) entre as médias das três faixas etárias estudadas. Em relação à área rural e urbana, a média da relação DO/CO para cada faixa etária, observa-se que há uma tendência significativa de médias menores na zona rural. O mesmo ocorre quando são calculadas as proporções de soropositivos. CONCLUSÃO: Os resultados obtidos mostraram que o percentual e indivíduos com anticorpos da classe IgG contra a rubéola na faixa etária de 20-29 anos foi abaixo aquela observada em faixas etárias inferiores ou superiores. Além disso, a diferença da soropositividade entre a zona urbana e rural traduz uma suscetibilidade com potencial de manter a circulação do vírus nesta região.OBJECTIVE: To investigate seroprevalence of rubella antibodies in a 15 to 39 year old population in the municipal district of Guaratinguetá. METHODS: The 996 samples studied were collected in urban and rural zones, after informed and elucidated consent from men and women stratified by age (15 -39 years). Rubella IgG antibodies were detected by ELISA using the commercial kit Rubenostika IgGII (Organon Teknika THE, Holland). Age groups were stratified in 3 categories: 15-19; 20-29 and 30-39 years of age. Statistical analyses were accomplished with the software MINITAB version 14.0 (Minitab Inc, USA). RESULTS: The proportion of seropositives for antibodies of the IgG class were: 92.7.% positive for 15-19 years; 82.4% for 20 to 29 years and 90.7% for 30-39 years, with a significant difference in the seropositive proportions by age group (p <0.001). Variation of intensity of antibody response was calculated and results show a significant difference (p = 0.002) between means of the 3 age groups studied. In relation to rural and urban zone average of the ratio DO/CO for each age group, a significant tendency towards a lower average was observed in the rural zone. The same was true when the seropositive proportions were calculated. CONCLUSION: Results showed that the percentage and individuals with antibodies of the IgG class against rubella in the 20-29 year age group was lower than that in the younger and older age groups. Furthermore, the difference between seropositivity in the urban and rural zones discloses susceptibility with a potential for continued circulation of the virus in this zone
WHO-ISG collaboration on assistive technologies for healthy ageing-in-place: A round table discussion
Assistive Technology (AT) is used at various points in the lifespan by those coping with either short-term or long-term impairments, which can involve living with chronic conditions and/or comorbidities. In the case of older adults, AT can support or compensate for the functional or cognitive declines that they are likely to face in later life. AT can be integrated as part of smart homes (see Figure 1 from van Dijken et al, 2006); and should be safe to use, effective, easy to access, affordable, and not seen as stigmatising. In addition, AT should support older adults to have a meaningful life while building self-esteem, and autonomy and promoting social participation and community engagement. For this roundtable discussion, we present and discuss a WHO-ISG collaborative project focused on Assistive Technology for Healthy Ageing. For this project, we consider applications and use AT not only from a medical standpoint but also situated within a social perspective in the context of Gerontechnology. Results and propositions according to the WHO-UNICEF global report on assistive technology were applied as a starting point for this project (WHO, 2022), prioritising the potential benefits to individuals, their communities, and society and with a focus on identifying potential barriers that may occur and how to mitigate them